Table 1.

Participant characteristic

Demographic data
Age (years)	65 (57; 71)
Sex (male)	63%
Body mass index (kg/m2)	31.4 ± 5.6
Normal range (18–25)	13%
Overweight (25–30)	27%
Obese class I (30–35)	36%
Obese class II–III (> 35)	24%
Disease duration (years)	10 (5; 17)
Smoking habits
Current smoking (yes)	3%
Social smoking (yes)	2%
Previous smoking (yes)	40%

Medications
Antidiabetic medications (yes)	93%
Biguanides	78%
SGLT-2 inhibitors	25%
DPP-4 inhibitors	18%
Sulfonylureas	9%
Insulin (yes)	26%
Long-acting	26%
Dose (IU)	50 (40; 92)
Short-acting	7%
Dose (IU)	22 (9; 100)
Antihypertensives (yes)	68%
ACE-inhibitor	32%
β-blocker	17%
Statins (yes)	70%

Biochemistry
Fasting glucose levels (mmol/L)	8.9 (7.5; 10.4)
Haemoglobin A1c (mmol/mol)	55 (48; 62)
Cholesterol (mmol/L)	3.9 ± 0.9
Triglyceride (mmol/L)	1.4 (1.0; 2.0)
Low density lipoprotein (mmol/L)	1.9 (1.4; 2.4)
High density lipoprotein (mmol/L)	1.2 (1.0; 1.5)
eGFR	89 (73; 90)
Creatinin	8607 (5774; 13,190)
Albumin	0.01 (0.006; 0.019)
ALAT	27 (21; 37.5)

SGLT sodium-glucose linked transporter; DPP dipeptidyl peptidases; ACE angiotensin-converting enzyme; eGFR estimated glomerular filtration rate; ALAT alanine aminotransferase